A recent review in the journal Nature Reviews Clinical Oncology has explored new therapeutic approaches for multiple myeloma (MM) targeting cell membrane proteins.

SystImmune, Inc. has received FDA approval for its IND application regarding BL-M11D1 for patients with relapsed or refractory acute myeloid leukemia.

Repare Therapeutics has initiated dosing for the first patient in a Phase 1 clinical trial of RP-3467, an inhibitor of Polθ ATPase.

Dong-A ST declared that its biosimilar Imuldosa™ (ustekinumab-srlf/DMB-3115), which references Stelara®, has received approval from the U.S. Food and Drug Administration (FDA).

The FDA has authorized Pfizer's HYMPAVZI™ (marstacimab-hncq) for use in adults and teens with hemophilia A or B who do not have inhibitors.

Sutro Biopharma, is a clinical-stage oncology firm that specializes in innovative, site-specific antibody-drug conjugates (ADCs).

The FDA has sanctioned Genentech's Itovebi, a focused therapy for advanced hormone receptor-positive, HER2-negative breast cancer that carries a PIK3CA mutation.

European Medicines Agency Approves Marketing Application for AVT03, a Biosimilar Candidate to Prolia® and Xgeva®.

Immatics Releases Phase 1b Results for ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma and Updates on Upcoming SUPRAME Phase 3 Trial.

Foghorn Therapeutics reports the dosing of its first patient in a Phase 1 trial of FHD-909, a novel oral inhibitor targeting SMARCA2 for solid tumors with SMARCA4 mutations.

TREMFYA® (guselkumab) shows remarkable outcomes in patients with Crohn's disease and ulcerative colitis, both those who haven't received biologics and those who have not responded to them.

Pfizer has revealed encouraging topline findings from the final pre-specified overall survival (OS) assessment of the TALAPRO-2 trial involving TALZENNA® (talazoparib).